Q3 2025 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-283094
The Brief · Bain Capital Life Sciences Investors, LLC · Q3 2025
AI · grounded in 13F
Bain Capital Life Sciences Investors, LLC established a new position in HeartFlow Inc HTFL valued at $419M. The fund also initiated new stakes in NewAmsterdam Pharma Company NAMS for $304.8M and Cidara Therapeutics Inc CDTX for $289.3M. Other new additions include Pharvaris N V PHVS, Olema Pharmaceuticals Inc OLMA, and Savara Inc SVRA. Total assets under management stand at $1.5B across 21 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 42238D107 | HTFL | HEARTFLOW INC | $419.0M | 27.8% | 12,448,158 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $304.9M | 20.2% | 10,719,110 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $289.3M | 19.2% | 3,020,990 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $79.4M | 5.27% | 3,181,275 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $67.0M | 4.45% | 6,843,954 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $62.8M | 4.17% | 17,600,621 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $51.8M | 3.44% | 1,315,892 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $48.8M | 3.24% | 7,911,669 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $45.9M | 3.05% | 2,439,538 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $28.2M | 1.87% | 8,434,560 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $22.8M | 1.51% | 2,712,008 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $22.6M | 1.50% | 9,677,125 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $20.2M | 1.34% | 3,368,370 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $16.0M | 1.06% | 5,249,069 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $8.3M | 0.55% | 2,436,588 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $7.2M | 0.48% | 2,485,638 | Common | SOLE |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $3.8M | 0.26% | 4,566,817 | Common | SOLE |
| 59045L205 | MRSN | MERSANA THERAPEUTICS INC | $2.7M | 0.18% | 346,545 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $2.5M | 0.16% | 1,111,910 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $1.8M | 0.12% | 3,538,609 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.7M | 0.11% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.